Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
Clinical Neurology and Neurosurgery|May 31, 2022
Shared pathophysiology: Understanding stroke and Alzheimer's diseaseSai Sriram, Yusuf Mehkri, Stephan Quintin, et al.
Brain Communications|October 10, 2025
Uncovering α-synuclein and tau burden in Alzheimer's and Lewy body diseasesStephan Quintin, Giavanna Paterno, Grace M Lloyd, et al.
Exploration of Targeted Anti-Tumor Therapy|November 7, 2022
Steroid utility, immunotherapy, and brain tumor management: an update on conflicting therapiesMatthew Goldman, Brandon Lucke-Wold, Meleine Martinez-Sosa, et al.
BMC Infectious Diseases|November 27, 2023
Meta-analysis of the role of neutrophil to lymphocyte ratio in neonatal sepsisJingyang Chen, Sanaz Yasrebinia, Arshin Ghaedi, et al.
Acta Neuropathologica Communications|June 10, 2024
A multiverse of α-synuclein: investigation of prion strain properties with carboxyl-terminal truncation specific antibodies in animal modelsGrace M Lloyd, Stephan Quintin, Zachary A Sorrentino, et al.
Acta Neuropathologica|April 30, 2022
Unique seeding profiles and prion-like propagation of synucleinopathies are highly dependent on the host in human α-synuclein transgenic miceGrace M Lloyd, Zachary A Sorrentino, Stephan Quintin, et al.
Cancers|June 26, 2026
Emerging Perspectives on Adverse Childhood Experiences and Brain Cancer ImmunotherapyJohn W Figg, Julian Mark, Caretia J Washington, et al.
The Journal of Biological Chemistry|June 12, 2023
Cellular processing of α-synuclein fibrils results in distinct physiological C-terminal truncations with a major cleavage site at residue Glu 114Stephan Quintin, Grace M Lloyd, Giavanna Paterno, et al.
Acta Neuropathologica Communications|July 23, 2023
Carboxyl truncation of α-synuclein occurs early and is influenced by human APOE genotype in transgenic mouse models of α-synuclein pathogenesisGrace M Lloyd, Brooke Long, Stephan Quintin, et al.
Pageof 2